首页> 外文期刊>Acta clinica Croatica >Electrophysiological effects, efficacy and safety of intravenous propafenone in termination of atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia: A prospective non-randomized interventional study
【24h】

Electrophysiological effects, efficacy and safety of intravenous propafenone in termination of atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia: A prospective non-randomized interventional study

机译:静脉注射普罗帕酮终止房室结折返性心动过速和房室折返性心动过速的电生理作用,疗效和安全性:前瞻性非随机干预研究

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this prospective, non-randomized interventional study was to assess electrophysiological effects, efficacy and safety of intravenous propafenone in termination of atrioventricular nodal reentrant tachycardia (AVNRT) and orthodromic atrioventricular reentrant tachycardia (AVRT). This single-center study was carried out at Department of Cardiology, Sestre milosrdnice University Hospital in Zagreb, Croatia, between January 1, 2005 and December 31, 2006. Eligibility requirements were fulfilled by a total of 70 patients with AVNRT (n=37) and AVRT (n=33). The intervention consisted of the electrophysiological study aimed at inducing tachycardia, followed by intravenous administration of 2 mg/kg propafenone in both groups. The main outcome measures were safety and efficacy of 2 mg/kg intravenous propafenone in tachycardia termination and re-induction. Out of 37 patients with AVNRT, propafenone managed to terminate it in 28 (75.7%) patients, while tachycardia was not inducible in 25 (67.56%) patients. Out of 33 patients with AVRT, propafenone managed to terminate AVRT in 29 (87.9%) patients, while tachycardia was not inducible in 22 (66.66%) patients. The overall propafenone efficacy in tachycardia termination was 81.42%. No propafenone-related adverse effects were recorded during the study period. Propafenone was found to be a safe and effective anti-arrhythmic drug and can be justifiably administered for AVNRT and AVRT termination. It could be considered as an alternative to adenosine and verapamil.
机译:这项前瞻性,非随机性干预研究的目的是评估静脉注射普罗帕酮在房室结折返性心动过速(AVNRT)和正畸性房室折返性心动过速(AVRT)终止中的电生理作用,疗效和安全性。该单中心研究于2005年1月1日至2006年12月31日在克罗地亚萨格勒布Sestre milosrdnice大学医院心内科进行。共有70例AVNRT患者(n = 37)满足了入选条件。和AVRT(n = 33)。干预包括旨在诱发心动过速的电生理研究,然后两组静脉注射2 mg / kg普罗帕酮。主要结局指标是2 mg / kg静脉注射普罗帕酮在心动过速终止和重新诱导中的安全性和有效性。在37例AVNRT患者中,普罗帕酮在28例(75.7%)患者中成功将其终止,而在25例(67.56%)患者中无法诱发心动过速。在33例AVRT患者中,普罗帕酮成功终止了29例(87.9%)患者的AVRT,而22例(66.66%)患者无法诱发心动过速。普罗帕酮在心动过速终止中的总疗效为81.42%。在研究期间未记录与普罗帕酮相关的不良反应。已发现普罗帕酮是一种安全有效的抗心律不齐药物,可以合理地用于AVNRT和AVRT终止治疗。它可以被认为是腺苷和维拉帕米的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号